Corvus Pharmaceuticals (CRVS) Shares Outstanding (Diluted Average) (2016 - 2025)

Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) history runs 10 years deep, the most recent figure standing at $75.2 million for Q1 2025.

• In Q1 2025, Shares Outstanding (Diluted Average) rose 53.25% year-over-year to $75.2 million; the TTM figure through Mar 2025 stood at $75.2 million (up 53.25% YoY), while the FY2024 annual figure was $61.0 million, up 26.99% from the prior year.
• Shares Outstanding (Diluted Average) was $75.2 million for Q1 2025 at Corvus Pharmaceuticals, up from $61.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $75.2 million in Q1 2025 to a low of $34.5 million in Q1 2021.
• Historically, Shares Outstanding (Diluted Average) has averaged $48.0 million across 5 years, with a median of $46.6 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Diluted Average) gained 0.01% in 2023, then soared 53.25% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $41.9 million in 2021, then rose by 11.23% to $46.6 million in 2022, then climbed by 3.16% to $48.0 million in 2023, then advanced by 26.99% to $61.0 million in 2024, then advanced by 23.23% to $75.2 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $75.2 million (Q1 2025), $61.0 million (Q4 2024), and $49.0 million (Q1 2024), per Business Quant data.